Oncolytic virus delivery: from nano-pharmacodynamics to enhanced oncolytic effect by Yokoda, Raquel (Author) et al.
© 2017 Yokoda et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. 
php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work 
you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For 
permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
Oncolytic Virotherapy 2017:6 39–49
Oncolytic Virotherapy Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
39
R e V i e w
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/OV.S145262
Oncolytic virus delivery: from nano-
pharmacodynamics to enhanced oncolytic effect
Raquel Yokoda1
Bolni M Nagalo1
Brent Vernon2
Rahmi Oklu3
Hassan Albadawi3
Thomas T DeLeon1
Yumei Zhou1
Jan B egan1
Dan G Duda4
Mitesh J Borad1
1Division of Hematology Oncology, 
Department of Medicine, Mayo 
Clinic, Scottsdale, 2Department of 
Biomedical engineering, Arizona 
State University, Tempe, 3Division of 
Vascular and interventional Radiology, 
Department of Radiology, Mayo 
Clinic, Scottsdale, AZ, 4Department 
of Radiation Oncology, Massachusetts 
General Hospital, Boston, MA, USA
Abstract: With the advancement of a growing number of oncolytic viruses (OVs) to clinical 
development, drug delivery is becoming an important barrier to overcome for optimal therapeu-
tic benefits. Host immunity, tumor microenvironment and abnormal vascularity contribute to 
inefficient vector delivery. A number of novel approaches for enhanced OV delivery are under 
evaluation, including use of nanoparticles, immunomodulatory agents and complex viral–particle 
ligands along with manipulations of the tumor microenvironment. This field of OV delivery 
has quickly evolved to bioengineering of complex nanoparticles that could be deposited within 
the tumor using minimal invasive image-guided delivery. Some of the strategies include ultra-
sound (US)-mediated cavitation-enhanced extravasation, magnetic viral complexes delivery, 
image-guided infusions with focused US and targeting photodynamic virotherapy. In addition, 
strategies that modulate tumor microenvironment to decrease extracellular matrix deposition and 
increase viral propagation are being used to improve tumor penetration by OVs. Some involve 
modification of the viral genome to enhance their tumoral penetration potential. Here, we high-
light the barriers to oncolytic viral delivery, and discuss the challenges to improving it and the 
perspectives of establishing new modes of active delivery to achieve enhanced oncolytic effects.
Keywords: oncolytic viruses, oncolytic virotherapy, drug delivery systems, tumor 
microenvironment
Introduction
Efficient delivery of oncolytic viruses (OVs) remains a major challenge in the field of 
oncology limiting their therapeutic effect. This may account for the disparity between 
in vitro and in vivo preclinical studies1,2 and the relatively modest antitumor effects 
observed thus far in clinical trials.3
Three major limitations need to be addressed to enhance delivery: first, virus 
bioavailability determined by the host vascular dynamics, perfusion parameters and 
innate immune responses;4–6 second, OV biodistribution and propagation,7–9 usually 
impaired by the intra-tumoral microenvironment heterogeneity; and third, the amplifi-
cation of the virus bystander killing effect by cell-to-cell contact or by intrinsic vector 
enhancement.5 In this review, we discuss these three aspects and provide alternatives 
to improve them.
A number of prior studies have been done to optimize systemic delivery of OVs.10–12 
Although a systemic approach is still a major goal of therapy given its simplicity, it has 
been difficult, and clinical trials employing systemic delivery have had limited success 
thus far.3,4,13 Even locoregional approaches of administration – such as  intraperitoneal 
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delivery for ovarian cancer,14 intrapleural delivery for meso-
theliomas,15 intracavitary delivery for gliomas16 and intrader-
mal delivery for melanomas17 – have yielded inconsistent 
results in both preclinical and clinical studies. Despite the 
difficulties for a viral vector to reach and eventually infect 
extravascular tumor cells, the main mode of administration 
has remained direct intravascular infusion through a major 
vessel supplying the tumor or by local intra-lesional injection 
in a solid tumor, with some studies employing both modes of 
administration.14,18 As a result, the intra-lesional approach has 
been preferred due to limited viral inactivation by the innate 
immune system, lower probability of systemic toxicity and 
optimal delivery of viral load in a single dose. Nonetheless, 
intra-tumoral delivery needs to be enhanced given the pres-
ence of a heterogeneous extracellular matrix (ECM) and the 
fact that transvascular perfusion may not be achieved to a 
therapeutic level. Inasmuch as tumor neovasculature is often 
abnormal, it severely impacts the intra-tumoral spread of OVs 
and maintenance of viral propagation. Tumor angiogenesis 
results in heterogeneous pericyte coverage promoting tran-
sient perfusion, leading to a hypoxic and acidic microenviron-
ment, with tendency to microvasculature coagulation. This 
leads to suboptimal infection, impacts treatment resistance 
and may result in tumor recurrence.19–21 In view of this, vec-
tor enhancement has been equally important to improve the 
potential of the virus platform.
The host complex and viral vector 
bioavailability
Strategies for improving vector delivery include shield-
ing of the virus from host immune defenses, and the use 
of nanoparticles for active targeting and nanofilaments to 
improve vector propagation.
Shielding and surface modifications
Shielding is done by cell-based delivery approaches22 listed in 
Table 1, or through an interface with nanoparticle  carriers.23 
The first relies on passive delivery, given that direction and 
flow of viral propagation is dependent solely on the cell-based 
properties towards the target organ or tissue. The latter relies 
on active delivery, where nanoparticle physical properties 
can be used to promote monitoring and targeting of a spe-
cific organ. In this case, shielding may be done by physical 
interface with biomaterials such as encapsulation and coating 
with polymers, or biodegradable nanoparticles, liposomes or 
copolymers.24 It can also be achieved by chemical modifica-
tion with biomaterials such as polyamidoamine, polyethylene 
glycol (PEG), poly-N-(2-hydroxypropyl) methacrylamide, 
polysaccharides, bioreducible polymers, arginine-grafted 
bioreducible polymers, cationic polymers, poly-ethylenimine, 
poly-L-lysine and cationic lipids.24–26 Another way of shielding 
with biomaterials is through immobilization of the vector to a 
material’s surface through a process termed reverse transfec-
tion, solid-phase delivery or substrate-mediated delivery. This 
may also provide controlled viral release rate, localizing the 
gene expression to the surroundings, diminishing systemic 
infectivity, maintaining an elevated local concentration and as 
such helping to overcome transport limitations. Other similar 
biomaterials include microporous scaffolds, hydrogels, silk-
elastin-like polymers, recombinant polymers, alginate and 
poly (lactic-co-glycolic acid), chitosan, fibrin and collagen 
micelles.23,25 Both cell-based and biomaterial interface-based 
delivery approaches are summarized in Table 1.
Using physical properties of nanoparticles 
to enhance active delivery and vector 
propagation
Active delivery is desirable over passive delivery as transvas-
cular extravasation leads to the same constraints for nano-
therapeutic viral delivery that have been described for other 
nanotherapy approaches.19,51 In this sense, the modulation 
of the tumor microenvironment is fundamental to enhance 
tumor spread.
Specific biomaterials possess properties required to allow 
delivery of viral vectors through ultrasound (US) using micro-
bubbles (MBs) and focused sonoporation.52–54 While using 
MBs, contrast is employed for US using inert gas to pre-produce 
MBs that are injected at the tumor followed by percutaneous 
US, with shocking waves propelling the MBs against the tumor 
matrix causing temporary cavitation which may considerably 
enhance OV delivery through increased extravasation.
Another strategy for improved real-time monitoring of 
delivery includes magnetic-viral complexes, detected by 
magnetic resonance55,56 which enables noninvasive therapy 
monitoring. From the active propagation perspective, nano-
filaments57 can be used to enhance viral propagation, in a way 
comparable to the spontaneously formed tunneling nanotubes 
in mesothelioma cells. The goal is to use ultrafine actin-based 
cytoplasmic extensions for increased bystander killing due 
to amplification of cell-to-cell contact.
Appropriate control of viral delivery can also be achieved 
by nanoparticles. Some techniques provide the particles 
with stimuli-responsive properties for enabling antitumoral 
effect. An example is photodynamic virotherapy, where the 
particle–viral ligand is armed with a genetically encoded 
 photosensitizer, such as photofrin or talaporfin,58 which 
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Table 1 Selected examples of shielding the OV from host barriers
Strategy Approach Viral 
platform
Tumor type Outcome References
Cell-based 
delivery
Mesenchymal stem cell 
(bone marrow derived)
MV Liver cancer evasion of host immunity in setting of 
systemic delivery
27
Mesenchymal stromal cell Ad Pancreatic tumor Decreased expression of CD24 and Ki67 
and enhanced activity of caspase-3
28
Neural stem cell Ad GBM Single administration of oncolytic virus-
loaded NSCs allows for up to 31% 
coverage of intracranial tumors
29
Activated T-cells VSV Ovarian cancer Increased efficiency compared to 
nonactivated T-cells
30
immortalized cell line 
from solid tumor
VSV Murine model 
metastatic tumors
ease of manipulation and propagation in 
vitro, but has a tendency to arrest in the 
small capillary beds of the lungs and fail to 
recirculate in animal (mice) model
31
HeLa (cervical carcinoma)
A549 (lung carcinoma)
MCF-7 (breast carcinoma)
CT26 (colorectal 
carcinoma)
SF268 (glioblastoma)
Dendritic cells MV Breast cancer Prevention of pleural exudate in a 
xenograft model
32
Sickle cell Reovirus 
VSV
Melanoma Absorption and transfection despite 
presence of neutralizing antibodies
33
Macrophages Ad Prostate cancer Abolishment of tumor regrowth 34
Myeloid-derived 
suppressor cells
VSV Metastatic colon 
tumor
Robust immunosuppressive activity, 
preferential migration to tumor and 
decreased toxicity
35
Monocytes Ad Syrian hamster models 
of cancer
Antitumoral effect after multiple dosing 36
Ghost erythrocytes VSV-G in vitro transfection Improved transfection efficiency 37
Physical interface 
with biomaterials
encapsulation (within 
biomaterial) alginate
Ad Model for shielding the 
adenoviruses
enhanced transgene expression and 
reduced immune response
38
encapsulation (within 
biomaterial) PLGA
Ad Model for shielding the 
adenoviruses
enhanced transgene expression and 
reduced immune response
38
Surface modification 
coating with 
biodegradable 
nanoparticles (PNLG)
Ad Model for shielding the 
adenoviruses
Improved efficacy and safety 39
Chemical 
modification with 
biomaterials
PAMAM dendrimer-
coated
Ad eGFR+ cells Increased transduction efficiency, 
especially in low-to-medium CAR-
expressing cancer cell lines
40
Cationic polymers* (form 
electrostatic interactions 
with anionic Ad, can also 
be classified as physical 
interface)
Ad Model for shielding the 
adenoviruses
Permitted ligand attachment and 
manipulation of molecular weight
25
PLL (cationic polymer*) Ad Model for shielding the 
adenoviruses
Caused Ad to bind and infect cells through 
a pathway other than classic CAR-
mediated entry
41
PeG-PLL-Ad had gene expression ~4× 
compared to naked Ad
Cationic lipids* Ad Model for shielding the 
adenoviruses
increased delivery ~80× compared to 
naked Ad
42
Liposomes Resulted in effective immune shielding
PeGylation (covalent 
chemical modification)
Ad Model for shielding the 
adenoviruses
increased circulation half-life 43
VSV Protected from neutralization
Poly-HPMA Ad Model for shielding the 
adenoviruses
increased half-life by diminishing hepatic 
transgene expression
44
(Continued)
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provides light-induced antitumor effect when activated at 
a specific wavelength. Another approach is deployment of 
a synthesized pH-sensitive polymer with a bioreducible 
disulfide bond (methoxy-pegylated cystaminebisacryl-
amide) armed to release the viral particle load in an acidic 
 environment.59 Particle ligand approaches have also been 
used to target the tumor. An example of such an approach 
is the use of penetrating peptides or homing peptides60 such 
as arginylglycylaspartic acid (Arg-Gly-Asp) which are fre-
quently used as a targeting moiety in adenovirus/polymer 
complexes with high affinity for αv integrins,61 E-selectins62 
and vascular endothelial growth factor (VEGF) receptors.63 
Target ligands can also be growth factors or antibodies such 
as cetuximab, and even natural ligands such as folate and 
chitosan PEG-folic acid.64 Active delivery approaches using 
virus–particle ligand complexes are summarized in Table 2. 
Some of those strategies may facilitate the induction of virus 
persistence by evasion of the DNA and RNA sensing systems 
and thereby help to improve oncolytic effect. On the top of 
that, further effects on viral replication and necessary viral 
load for each type of nanoparticle used and specific target 
organ still need to be evaluated in a case-by-case fashion.
Biomaterials shielding for improving 
monitoring and control of vector release
Biomaterial shielding has been important to diminish 
peripheral sequestration and to improve targeting by using 
specific ligands, while ensuring that size and molecular shape 
remain fairly uniform. This allows to predict hemodynamic 
interactions at a certain body temperature and blood viscos-
ity depending on the polymer type used such as molecule, 
protein72 or hydrogels. This strategy also allows for prediction 
of the potential rate of viral release at the tumor level.73 In 
the long run, biomaterials may help track and predict viral 
delivery within reliable ranges. From this perspective, co-
polymerization can result in enhanced tumor penetration. 
Similarly, optimal water solubility has been achieved by 
introducing a pH-sensitive cleavable linker and target moiety 
to a multi-arm copolymer and ultimately complexing it with 
viral particles.74,75
The tumor microenvironment: 
perfusion, permeability and 
retention
On one level, the more bioavailability a vector achieves inside 
the tumor, the more optimal the killing effect. On the other 
level, bioavailability can be increased by manipulation of host 
hemodynamics. Improving perfusion pressure may have an 
impact in a short window of time for locally administered 
compounds, as listed in Table 3. Animal studies have shown 
that promoting a hypertensive state through exercise also 
promotes extravasation for OV administration.76 Mayo Clinic 
studies8,76 have proposed a mathematical model of radial 
expansion and conflation of intra-tumoral infectious centers. 
Strategy Approach Viral 
platform
Tumor type Outcome References
Polysaccharides Ad Model for shielding the 
adenoviruses
Unable to evade neutralizing antibodies 45
Substrate-
mediated viral 
gene delivery
Hydrogel Ad Model for shielding the 
adenoviruses
Minimized sequestration by the 
mononuclear phagocytic system
46
Silk-elastin-like polymer Ad Model for shielding the 
adenoviruses
increased viral gene expression but 
demonstrated some acute toxicity
47
Chitosan Ad Model for shielding the 
adenoviruses
infectivity was observed in cells that do 
not express CAR
48
Biogels: fibrin and collagen 
micelle based
Ad Model for shielding the 
adenoviruses
Sustained release of viral particles by fibrin 49
Microporous scaffolds 
(could be considered 
as physical interface 
given that coaxial 
electrospinning is used to 
encapsulate vectors)
Ad Model for shielding the 
adenoviruses
Reduced macrophage activation 50
Note: *Cationic polymers and cationic lipids may be classified as a way to stablish physical instead of chemical interface because they are formed by electrostatic interactions 
with anionic adenoviruses rather than through chemical conjugation.
Abbreviations: OV, oncolytic virus; MV, measles virus; Ad, adenovirus; GBM, glioblastoma multiforme; NSCs, neural stem cells; VSV, vesicular stomatitis virus; VSV-G, 
vesicular stomatitis virus glycoprotein G; PLGA, poly(lactic-co-glycolic acid); PNLG, poly[2-(dibutylamino)ethylamine-L-glutamate]; PAMAM, polyamidoamine; eGFR+, 
epidermal growth factor receptor positive; CAR, coxsackie adenovirus receptor; PLL, poly(L-lysine); PeG, polyethylene glycol; poly-HPMA, poly-N-(2-hydroxypropyl) 
methacrylamide.
Table 1 (Continued)
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This model also predicts the probability of tumor cell survival 
after the oncolytic phase and establishes perfusion pressure 
as a major determinant of intra-tumoral extravasation of OVs. 
The major impact was seen upon density of viral infection 
within the tumor achieved by increase and decrease in the 
mean arterial pressure.8,76
The focus on increasing permeability of tumor blood 
vessels has been critical since the enhanced perfusion and 
retention (EPR) effect was first described in 1986,77 exploit-
ing the leaky nature of tumor vasculature.9,78 Convection is 
compromised on account of the high intra-tumoral interstitial 
pressure, dense heterogeneous stroma, lack of fenestration 
in the tumor endothelium and heterogeneous basement 
membranes hindering lymphatic drainage and impeding 
viral extravasation, all diminishing the EPR effect.19 The 
extent to which the EPR effect observed in murine models 
may translate to the human disease setting remains unclear.25
The tumor microenvironment as a 
barrier to OV delivery
Unlike normal vasculature, intra-tumoral vessels are imma-
ture, chaotic and mostly saccular, with a tortuosity that 
highly impacts effective blood perfusion.79 Nonuniform 
endothelial structure that promotes leakage in nonspecific 
areas plus constant changes in the tumor environment 
due to tumor growth and treatment may partially explain 
why a primary tumor may respond to treatment whereas 
its metastases may be unresponsive. The leakier a tumor 
becomes, the higher the interstitial fluid pressure, as the 
endothelial cells may not maintain pressure gradients 
across the endothelial wall and the drainage by lymphatics 
is dysfunctional. Stasis increases local hypoxia triggering 
upregulation of HIF-1 alpha and VEGF pathway activity, 
leading to a vicious cycle.80 Blocking VEGF has been shown 
to transiently “normalize” vascular structure and function, 
Table 2 Selected examples of active delivery using complexes of virus–viral particle ligands
Strategy Nanoparticle ligand Virus Results References
Bioreducible disulfide 
bond
mPeG-PiP-CBA Ad Armed release of viral particle in hypoxic, 
acidic environment
59
Vascular zip code Linear RGD (Arg-Gly-Asp) Ad enhanced endocytic ability 65
CD-PeG-cRGD
Cyclic CD-PeG-cRGD Ad Downregulation of iCAM-1, VCAM-1, 
e-selectin, iL-6, iL-18, VeGF-A and Tie-2
66
Natural ligand (folate) PeG-folic acid Ad enhanced cell entry through folate receptors 67
Targeting ligands 
(antibodies)
Trastuzumab (HeR2/neu) Ad Retargeted viral receptor to breast cancer 
cells
68
Ad-PeG-HeR
Cetuximab-pHPMA-PeG Ad Retargeted viral receptor to intraperitoneal 
ovarian cancer cells
69
Targeting ligands 
(growth factors)
VeGF-pHPMA or bFGF-
pHPMA
Ad Retargeting evaded neutralizing antibodies 70
Biotin-eGF Ad Enhanced tumor specificity and membrane 
permeability
71
Abbreviations: mPeG-PiP-CBA, methoxy-pegylated pH-sensitive polymer cystaminebisacrylamide; Ad, adenovirus; RGD, arginylglycylaspartic acid; CD-PeG-cRGD, 
cyclodextrin pegylated arginylglycylaspartic acid; iCAM-1, intercellular adhesion molecule 1; VCAM-1, vascular cell adhesion molecule 1; iL, interleukin; VeGF A, vascular 
endothelial growth factor A; PeG-folic acid, pegylated-folic acid; HeR2/neu, human epidermal growth factor receptor 2/proto-oncogene neu; Ad-PeG-HeR, pegylated 
adenovirus conjugated to herceptin; Cetuximab-pHPMA-PeG, cetuximab-pegylated conjugated with poly-N-(2-hydroxypropyl) methacrylamide; VeGF-pHPMA, vascular 
endothelial growth factor conjugated with poly-N-(2-hydroxypropyl)methacrylamide; bFGF-pHPMA, basic fibroblast growth factor conjugated with poly-N-(2-hydroxypropyl)
methacrylamide; biotin-eGF, biotin conjugated with epidermal growth factor.
Table 3 Pharmacodynamic manipulation to enhance oncolytic virus bioavailability
Infusion type Drugs Effect References
Local Nitric oxide Local improvement of vasodilation and perfusion for short 
period of time (normalization window) with impact in  
normal tissues
80
Bradykinin
Nitroglycerin
Histamine
Local hyperthermia
Low-dose paclitaxel
Systemic Angiotensin receptor blockers Decreased collagen deposition improving trans matrix 
propagation
83
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perhaps explaining why anti-VEGF antibodies have shown 
clinical efficacy (increased overall survival) when combined 
with chemotherapy in patients with mesothelioma, colon, 
lung, ovarian or cervical cancers. It was hypothesized that 
anti-VEGF approaches improve tumor perfusion by nor-
malizing functionality of the tumor vasculature. The use 
of anti-VEGF and VEGF receptor therapies could enhance 
viral delivery in selected patients as well, akin to how these 
therapies have been enhancing immunotherapy.81 Similarly, 
another approach to normalize nitric oxide gradients to 
recover vessel function has been described.82
Another obstacle to viral penetration is the ECM, par-
ticularly in highly desmoplastic tumors, where nanoparticles 
injected directly inside the tumor are unable to move far 
from the injection site.84,85 One study co-injected local intra-
tumoral bacterial collagenase with oncolytic herpes virus for 
melanoma treatment, and the distribution area of the OVs was 
found to increase threefold.86 Given that collagen is an inte-
gral structural component of the vascular wall, collagenase 
may never be used systemically. An alternate approach is to 
use an anti-fibrotic agent that can diminish collagen such as 
relaxin, which is known for reorganizing collagen during 
pregnancy, and has been shown to increase tumor penetration 
by OVs after 2 weeks.87 Another option is to use the metal-
loproteinase-1 and -8, which have been shown to increase 
OV delivery, improving distribution and yielding improved 
efficacy.88 A novel use for antihypertensive drugs from the 
angiotensin II receptor blocker class has been to modulate 
transforming growth factor beta activation and decrease col-
lagen deposition.89 This mode of action has been employed 
in the prevention of esophageal sclerosis due to eosinophilic 
esophagitis. Losartan was the first candidate drug to be evalu-
ated for decreasing collagen deposition in the tumor micro-
environment. Dramatic decreases in collagen deposits and 
increase in tumor penetration were observed after 2 weeks.83 
Another study in non-hypertensive patients with pancreatic 
adenocarcinoma demonstrated that use of candesartan was 
associated with a 6-month longer survival compared with the 
control group.90,91 In patients with hepatocellular carcinoma, 
candesartan downregulated the expression of VEGF-A, via 
the angiotensin II type I receptor, suggesting that it might 
be useful to inhibit angiogenesis in liver cancer.92 Studies 
with prostaglandin-I2 analogs have also demonstrated their 
efficiency in promoting vascular blood flow enhancement 
and extravasation at the tumor microenvironment, but safety 
studies must be performed prior to evaluating their potential 
for drug development.93
Intrinsic vector enhancement, 
selective replication and retargeting 
viral tropism
Therapeutic safety of vectors is proportional to their tumor 
target selectiveness. Selective targeting using tumor-specific 
promoters ensures that viral replication will be restricted to 
cancerous tissues while healthy tissues will remain unharmed. 
Examples of tumor-specific promoters are provided in 
Table 4. Another approach is to restrict tropism, and thereby 
enhance selectivity, by retargeting infection by a virus while 
ablating its ability to infect cells through its natural recep-
tors.94 Instead, viruses are hexon swapped95 and pseudotyped 
with a more potent entry gene, or by fusing the entry gene to 
a single-chain antibody against upregulated tumor-specific 
receptors.96–98 To sum up, arming recombinant viruses with 
prodrug convertases, cytokines, and pH-releasing arms using 
a variety of envelopes, capsids and fibers may onset viral 
proteases only in a cancer-specific environment.99 Arming 
the viruses with a prodrug convertase will enable them to 
transform a nontoxic substrate or metabolite into a lethal 
drug within the tumor environment. Using this approach, the 
inclusion of cytotoxic genes and suicide genes was instituted 
in a herpes simplex virus (HSV) encoding thymidine kinase 
Table 4 Selected examples of tumor-specific promoters
Tumor target Virus-encoded promoter Viral platform References
Bladder cancer Uroplakin ii Ad 131
Brain tumors Nestin HSV-1 132
Musashi-1 HSV-1 133
Breast cancer estrogen response element Ad 134
Gastroenteropancreatic neuroendocrine tumors Chromogranin-A Ad 135
Glioma Glial fibrillary acidic protein Ad 136
Hepatocellular carcinoma Alpha-fetoprotein Ad, HSV-1 137
Melanoma Tyrosinase Ad 138
Mesothelioma Mesothelin Ad 139
Ovarian cancer and breast cancer Mucin-1 Ad 140
Abbreviations: Ad, adenovirus; HSV-1, herpes simplex virus-1.
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(TK) to sensitize dividing cells to ganciclovir.100 Still another 
strategy involves introduction of single-stranded RNA 
tumor suppressor or lethal genes with enhanced cytopathic 
and apoptotic effect (ADP-overexpressed adenovirus).101 
Likewise, induction of autophagy can be accomplished 
by telomere-specific replication.102 Moreover, approaches 
where the virus may encode sequences for relaxin,103 deco-
rin,104 hyaluronidase,105 heparanase106 and elastase107 from 
macrophages metalloelastase have tested the concept of 
tumor microenvironment targeting viruses with intrinsic 
capabilities.
Immunomodulation at the tumor 
microenvironment
Oncolysis in cancer cells may be limited by immune 
response. Although most tumor cells have defective immu-
nomodulation and limited response to interferon (IFN) 
stimulation, normal cells can still sense the virus even if 
the progenies are replication deficient. Some viruses have 
developed mechanisms to evade or block the type-I IFN 
pathway at different levels.108 The most potent OVs are often 
wild types. First generations of OVs have been attenuated in 
an effort to achieve therapeutic safety, which led to reduced 
oncolytic potency. Hence, next generations are being engi-
neered by modifying molecular patterns in order to boost 
oncolytic effect without compromising safety. Therefore, 
particular attention has been given to viral evasion of the 
DNA or RNA cytoplasmic sensing mechanisms, antiviral 
IFN blockages and molecular or sub-particle interactions 
that may improve oncolytic efficacy.99,109,110 On one hand, the 
virus should escape recognition by the host. On the other 
hand, the virus genome can be made to enhance tumor cell 
killing by using stimulatory cytokines.111 These include 
tumor necrosis factor-related apoptosis-inducing ligand,112 
cytosine deaminase (CD),113 and immune-stimulatory 
cytokines genes such as interleukin (IL)-2,111 IL-12114 and 
IL-18.115 Some studies have employed a combination strat-
egy with a TK-CD hybrid protein116 to enhance killing and 
cancer specificity.
At the transcriptional level, inhibition of angiogenesis 
by viral encoding genes has been achieved using short 
hairpin RNA-expressing oncolytic adenovirus-mediated 
inhibition of IL-8 resulting in antiangiogenesis and tumor 
growth inhibition.117 Similarly, a VEGF-specific short 
hairpin RNA-expressing adenovirus has been developed118 
to block tumor growth and achieve potent inhibition of 
angiogenesis. These approaches exhibit ability of vector-
encoded RNA knockdown for OV delivery. In addition, a 
vaccinia virus armed with the soluble VEGF receptor 1 
protein developed antiangiogenic effect in a renal cancer 
cell model.119
Micro-RNA (miRNA) is evolving as a regulator of vector 
tropism,120,121 which is in contrast to the initial descriptions of 
RNA viruses where vector tropism could not be controlled 
through transcriptional targeting. This was evident in the case 
of coxsackievirus type A21, which causes off-target severe, 
often fatal myositis.122 miRNA techniques can promote 
detargeting of OVs during systemic administration, reshap-
ing tumor tropism. Several insertions of combined miRNA 
target sites can be adapted to a single vector to detarget pivotal 
organs at risk for off-target side effects.123
Short-interfering RNA (si-RNA)124 delivery systems have 
been designed to increase tumor specificity. Small double-
stranded RNAs impact posttranscriptional gene silencing 
as they target mRNAs that are then taken up by the RNA-
induced silencing complex.125 They can be used to bind and 
guide cleavage of mRNA in a sequence homology-dependent 
manner.126 These may limit side effects, and toxicity, and take 
oncolytic virotherapy to a new safety level. 
At the translational level, OV replication can be targeted 
by internal regulation of viral protein translation. This control 
is made through the internal ribosome entry site (IRES) ele-
ment and is becoming a powerful tool to co-express genes 
of interest from a single mRNA, as IRES appears to play 
the role of a translational enhancer and may soon expand 
perspectives for better vectors.127 As such, multiple genes 
in viral payloads can be delivered using intrinsic genomic 
attributes, to impact viral delivery.
Local spread of the virus can be boosted by immunosup-
pressive drugs, such as cyclophosphamide.128 Pulsed applica-
tion of immunosuppressive drugs is preferred, as seen with 
the prodrug 5-fluorocytosine and measles vaccine virus.129 
Other immunomodulators such as cobra venom factor may 
also facilitate infection with HSV.130
Future directions
There is a need in the field of OV delivery to explore natural 
tropism of therapeutically modified viral platforms, such as 
hepatitis viruses for hepatocellular cancer and encephalitic 
viruses for brain tumors. Thus far, natural tropism of viruses 
has not been vastly explored from an oncolytic viral perspective.
Delivery of multiple distinct therapeutic viral vectors at 
the same time using biomaterials to bypass the viral load 
sequestration and neutralization by the immune system has 
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not been attempted yet. This has the potential for simultane-
ous delivery of complementary viruses in an effort to achieve 
maximal synergy. Use of different viruses has been reported 
with better tumor penetration.141
Most current delivery approaches are passive in nature. 
Enhanced delivery could potentially be achieved using active 
delivery methods such as nanomachine-enabled propulsion 
of viral vectors. Simultaneously, the expectation is that active 
delivery could also contribute to the enoninvasive monitoring 
process of the OV targeting and propagation.
Improved monitoring methods for real-time viral injec-
tions and tagging viral particles for better in vivo visualization 
is also a growing necessity to assess viral delivery, especially 
for evaluating propagation after the first viral replication. 
To date, the gold standard for monitoring is biopsy. Bio-
luminescence and fluorescence optical methods are being 
developed along with noninvasive monitoring that allows 
deep tissue imaging. Examples of agents used for monitor-
ing are radiotracer-coupled surface transporters used as the 
sodium iodide symporter,142 human norepinephrine trans-
porter meta-iodobenzylguanidine which can be imagined 
by positron emission tomography or single photon emission 
computed tomography143 and human somatostatin receptor 
2 radiolabeled with indium-111 along with vaccinia virus.144
Conclusion
Delivery of OVs remains a major challenge in the field 
of oncology. Rapidly evolving, innovative bioengineering 
and molecular approaches, at the host, tumor and viral 
level, are currently being tested. Overcoming the barriers 
to OV delivery will be paramount to clinical translation. A 
multimodal strategy based on novel viral engineering, host 
defense manipulation and novel active delivery techniques 
is necessary for more successful cancer therapy.
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